Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
  • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
  • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
  • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
  • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/37—Esters of carboxylic acids
  • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/10—Anti-acne agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/16—Emollients or protectives, e.g. against radiation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/18—Antioxidants, e.g. antiradicals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/06—Free radical scavengers or antioxidants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
  • C07C39/205—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings
  • C07C39/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
  • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
  • C07C69/40—Succinic acid esters
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
  • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
  • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
  • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
  • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
  • C07C69/734—Ethers
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
  • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
  • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
  • C07C69/88—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with esterified carboxyl groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
  • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
  • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
  • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
  • C07D339/02—Five-membered rings
  • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
  • A61K2800/52—Stabilizers
  • A61K2800/522—Antioxidants; Radical scavengers

Definitions

• the invention relates to bioprecursors of biologically active molecules for cosmetic or therapeutic use. It aims in particular uses of said bioprecursors of molecules for cosmetic or dermatological use. It is also relative to the compositions containing such precursors and the associated methods of treatment.
• compositions are very extensive.
• active ingredients such as vitamins A, B, C, D, E and F used for their properties against overload, aging of the skin, drying, pigmentation, acne and certain skin diseases such as psoriasis or to promote healing or restructuring of the skin.
• Anoxidants are widely used in care products.
• the most used are the tocopherols and tocotrienols which represent a homogeneous family of products consisting of a hydroquinone residue substituted with one or more methyl groups and a polyisoprene chain more or less saturated.
• the most used are ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocotrienol.
• DL- ⁇ -tocopherol, a synthetic product is the usual form of vitamin E in topical specialties.
• antioxidants commonly used, mention may be made of polyphenols such as resveratrol, quercetin, luteolin, gallates, certain essential oils, ascorbyl palmitate, synthetic phenolic antioxidants such as butylated hydroxytoluene (BHT). and butylhydroxyanisole (BHA).
• polyphenols such as resveratrol, quercetin, luteolin, gallates, certain essential oils, ascorbyl palmitate, synthetic phenolic antioxidants such as butylated hydroxytoluene (BHT). and butylhydroxyanisole (BHA).
• BHT butylated hydroxytoluene
• BHA butylhydroxyanisole
• lipases, phosphatases, glucosidases, Glucocerebrosidases and sphingomyelinase are present in the Stratum corneum and esterases are present in the Stratum granulosum of the epidermis (UK Jain et al., Proceed Intern Symp., Control, ReI Bioact, Mater., 22, (1995)). Controlled Release Society, Inc., pp 702-703).
• EP-A-0 487 404 discloses the use of a glucosylated derivative of ascorbic acid in dermatological compositions. This derivative is hydrolyzed by cutaneous enzymes and releases ascorbic acid when these compositions are applied to the skin. But the use of such derivatives does not allow a quick release and sufficient amount of ascorbic acid on the surface of the skin.
• EP-A-0 710 478 discloses a product for topical application containing a precursor of a cosmetic or dermatological active ingredient (e.g. vitamins such as retinol, ascorbic acid) and a lipase.
• the precursor is an ester comprising at least one saturated or unsaturated, linear or branched chain ester function having from 2 to 25, preferably from 12 to 18, carbon atoms.
• a flavonoid serves as a base molecule on which it is grafted one or more molecules possessing UV radiation absorption properties. More specifically, the flavonoid carries radicals R 1 to R 5 which are chosen from -H, -OH and -OA, where A denotes the anti-UV agent.
• R 1 to R 5 which are chosen from -H, -OH and -OA, where A denotes the anti-UV agent.
• This document utilizes the UVA protection properties of flavonoids to provide a conjugate having an expanded UVA / B protection spectrum.
• Another major difficulty which is not solved by the previous teaching, is to ensure at the same time good tissue penetration if it is desired to deliver one or more active molecules, for example in the epidermis, the dermis and / or the hypodermis, and an effective antioxidant power in the various layers of the skin, including at the surface and in the Stratum corneum, in particular, and therefore an immediate or almost immediate antioxidant activity at the application on the skin.
• compositions which are storage stable and which can, after application to the skin, develop a sustainable activity having an effective antioxidant component at different levels of the skin, including on the surface (protective effect from the application or shortly after application) and in the Stratum corneum, able to penetrate into the lower layers. It would be of greater interest to combine a biological activity of another nature, for example at the level of the Stratum corneum, Stratum granulosum and / or the lower layers of the skin, for the purpose of therapeutic treatment, in particular. dermatological, or cosmetic.
• the invention therefore aims to provide molecules and compositions comprising them, to fulfill these objectives.
• PP represents a residue of a polyphenol in which each hydroxyl function is protected by an A group or a B group;
• - A is a substituted or unsubstituted, saturated or unsaturated alkyl chain comprising from 1 to 20 carbon atoms, preferably from 1 to 4, which is bonded to the polyphenol by: a carboxylic ester function on a hydroxyl function of said polyphenol; or
• n represents an integer greater than or equal to 1, especially 1, 2, 3, 4 or 5;
• B is a precursor of a biologically active molecule, which is bound to polyphenol by:
• a spacer B ' in which B is bonded to B' by a carboxylic ester function, and B 'is bonded to the polyphenol by a carboxylic ester function on a hydroxyl function of said polyphenol;
• m represents an integer greater than or equal to 1, in particular 1 or 2.
• the protective groups A may be identical or different.
• precursors B may be the same or different.
• the precursor (s) B which, like the groups A protect the hydroxyl functions of the polyphenol, are different from said groups A in that it further confers on the bioprecursor of the invention a therapeutic activity, in particular a dermatological or cosmetic activity. .
• the bioprecursor is capable of being biohydrolysed under the action of enzyme (s) of the skin to restore the hydroxyl functions, release said polyphenol and said biologically active molecule, present in the form of its precursor B in the bioprecursor.
• the "biopursor” of the invention is a "polyfunctional bioprecursor” comprising a polyphenol and at least one precursor B of a biologically active molecule.
• the bioprecursor of the invention allows controlled and progressive release of biologically active compounds and in particular in the different layers of the skin. This makes it possible in particular to improve the bioavailability of the biologically active compounds which are conveyed in the form of a bioprecursor compound. Indeed, it appears that certain hydroxyl functions of the polyphenol molecule can be released even though the bioprecursor is found in the upper parts of the skin, such as Stratum corneum, especially under the action of lipases. This allows the polyphenol to recover its antioxidant activity. The bioprecursor can thus have an antioxidant activity as soon as it is in contact with the skin and boy Wut
• the protective groups of the polyphenol are releasable only when the bioprecursor of the invention is placed under conditions where the biologically active molecules must act, which allows to exploit their properties optimally.
• the progressive release of biologically active compounds from the bioprecursor also makes it possible to avoid local over-concentrations and accumulation effects of the active molecules, which can cause irritation of the skin.
• the bioprecursor of the invention has in particular a very good skin penetration.
• Polyphenol can also be used as a transcutaneous vector for releasing a pharmaceutical active principle and make it bioavailable for non-dermatological applications.
• the pharmaceutical active ingredient released is intended to be subsequently transported by the blood.
• the bioprecursor of the invention also has the advantage of being perfectly stable in a cosmetic, dermatological or otherwise therapeutic, and to present no compatibility problem with the excipients and / or adjuvants generally used in said formulations. .
• the protective groups A stabilize the bioprecursor during storage but are easily hydrolyzed by the skin enzymes and hydrolysis begins shortly after contact with it, which allows the bioprecursor to quickly develop the antioxidant properties of polyphenol and the biologically active properties of the molecule B.
• the A groups also make it possible to modulate the kinetics of biohydrolysis of the bioprecursor and thus of the release of the active compounds.
• A is preferably derived from a linear carboxylic acid, branched or cyclic, for example selected from ethanoic acid, propanoic acid, linear or branched butanoic acid, caproic acid and lauric acid.
• biologically active molecule molecules of natural, artificial, synthetic or biotechnology origin, having a biological efficacy.
• the biologically active molecule has an effectiveness on the skin via biological targets in order to bring beneficial effects to the skin, for example to fight against drying, aging or pigmentation of the skin. skin, or to promote the restructuring of the skin or its cellular renewal.
• precursor B is meant a radical capable of being released, by enzymatic hydrolysis, in the form of a biologically active molecule.
• the biologically active molecule is a pharmaceutical active ingredient, and the precursor B is chosen accordingly.
• the biologically active molecule may be chosen from: an astringent molecule, an antioxidant molecule, an anti-free radical, anti-lipoperoxidant and / or anti-wrinkle molecule, a restructuring or biostimulant molecule, a photoprotective agent, such as an anti-UV molecule, a self-tanning agent, a hydrating molecule, a refreshing or heating molecule, a bleaching and / or anti-staining molecule, a slimming molecule, a molecule stimulating the microcirculation and / or vasculoprotective, an activator of tanning, a glycation inhibitor, an immunostimulatory molecule, an anti-inflammatory and / or anti-irritant agent, a refreshing molecule, a heating molecule, a flavoring molecule or a perfume molecule, etc.
• astringent molecule such as an anti-UV molecule, a self-tanning agent, a hydrating molecule, a refreshing or heating molecule, a
• the biologically active molecule may be chosen from: an antioxidant molecule, an anti-free radical molecule, a tanning activator, a bleaching and / or anti-staining molecule, a self-tanning agent, a photoprotective agent, an anti-UV molecule.
• the biological molecule is chosen from: polyphenol, lipoic acid, vitamins A, B, D, E, F, unsaturated or polyunsaturated organic acids, retinoic acids, hydroxy acids, polyols. 1 J
• astringent agents such as tannins
• moisturizing agents especially agents controlling skin perspiration such as saccharides (glucose, sorbitol, hyaluronic acid), but also glycerol and ⁇ -hydroxy acids, ceramides of plant origin, hydrating by their polar part, hydroxy acids, in particular lactic acid; agents for stimulating epidermal differentiation; agents promoting lipid synthesis;
• antioxidants are essential for the prevention and the treatment of the degradation of lipids, proteins and DNA under the action radicals as well as other damage to the biomolecules of the cutaneous surface, damages leading to the formation of wrinkles.
• microcirculatory and / or vasculoprotective stimulation agents such as vitamin P factors; examples: flavonoids, such as rutin, rutoside;
• tanning activators such as plant extracts and the peptides responsible for stimulating melanogenesis, for example peptide: acetyl-hexapeptide-1; whitening agents and / or stain removers: act by decreasing melanogenesis; example: resveratrol, vitamin C and its derivatives; self-tanning agents, especially skin surface pigments such as
• DHA dihydroxyacetone
• agents that inhibit glycation for example resveratrol, ⁇ -lipoic acid;
• immunostimulating agents for example: ⁇ -glucan, lentinan, deepsane; photoprotective agents, for example methoxycinnamates, for example octyl methoxycinnamate, octocrylene, hydroxybenzophenones, photoprotective salicylates, such as methyl or octyl salicylate; anti-inflammatory and / or anti-irritant agents, for example resveratrol, THC, luteolin; perfuming agents, such as vanillin, vanillate; refreshing agents, such as menthol; heating agents, such as vanillylbutyl ether.
• photoprotective agents for example methoxycinnamates, for example octyl methoxycinnamate, octocrylene, hydroxybenzophenones, photoprotective salicylates, such as methyl or octyl salicylate
• anti-inflammatory and / or anti-irritant agents for example res
• therapeutic molecules include steroid hormones produced in the cortex by the adrenal gland (in English "adrenal gland"), such as for example cortisol and aldosterone. These two hormones regulate glucose metabolism and salt excretion.
• Anti-inflammatory and anti-asthma agents such as prednisolone and prednisone, may also be mentioned.
• the precursor B comprises one or more OH alcohol functions, it may in particular protect them with a hydrocarbon protecting group, which may be of the same type as A, via a carboxylic ester function.
• a hydrocarbon protecting group which may be of the same type as A, via a carboxylic ester function.
• the precursors B comprising several OH functions are not preferred; advantageously, B is not a precursor of gallic acid or of one of its derivatives.
• Stilbenoids for example resveratrol; Flavonoids:
• Hydrolysable tannins polyesters of gallic and ellagic acids
• Phlorotannins e.g. fucofuroeckol
• Phenylpropanoids e.g. curcumin, caffeic acid and its derivatives, and in particular its esters, e.g. [[(2 E) -3- (3,4-dihydroxyphenyl) -1-oxo-2-propenyl] oxy] -
• curcuminoids for example tetrahydrocurcumin
• Aurones e.g. Aureuson
• Alkylpolyphenols e.g. Cardol
• Polyhydroxyphenyl amino acids e.g., hydroxytyrosine
• polyhydroxyphenylaminoalcohols e.g., adrenaline
• Anthracenone e.g., aloin
• Benzenediols e.g. pyrogallol
• benzenetriols e.g. pyrogallol
• Glycosylated polyphenols e.g. hesperidin, diosmin;
• polyphenol means a molecule comprising at least one aromatic benzene ring, optionally comprising one or more heteroatoms, and at least two OH alcohol functions.
• the aromatic rings may comprise no, one or more OH alcohol functions.
• the polyphenol is of the type comprising at least 2 phenol rings.
• B is 1, 2, 3, 4 or 5;
• X is N, S, O, CH, CH 2 , CO, NH;
• • represents a double or a single link; Represents a chain, optionally present, forming a 5- or 6-membered ring, including X and having one or more double bonds, optionally one or more OH substituents and / or one or more heteroatoms selected from N, S, O, located in cycle and / or substituting.
• the polyphenol may in particular also meet the following formula:
• a is 1, 2, 3, 4 or 5 and b is 1, 2, 3, 4 or 5, and preferably, a is 2 and b is 1.
• the polyphenol may also meet the following formula:
• Y is H or OH
• a is 1, 2, 3, or 4 and b is 1, 2, 3, 4 or 5, and preferably, a is 2 and b is 2.
• polyphenols are: resveratrol, luteolin, quercetin, hydroquinone, pyrocatechol, gallic acid, hydroxytyrosol, tetrahydrocurcumin, silylmarin, ellagic acid.
• the spacers A 'and B' may, independently of one another, be a hydrocarbon chain, preferably aliphatic, comprising at least two acid functional groups (especially diacid type) or at least one acid function and at least one hydroxyl function (especially hydroxy acid type) comprising from 2 to 13 carbon atoms, preferably from 2 to 5.
• These spacers may also carry other hydroxyl functions, acidic or amine.
• spacer a molecule allowing to bind, by ester functions, two molecules having hydroxyl functions.
• the spacer may also have an additional biological effect, such as, for example, a moisturizing effect for a hydroxy acid.
• a 'and B' are, independently of one another, a residue of succinic acid, adipic acid, brassylic acid, lactic acid, salicylic acid, or acid.
• the invention relates to the application of bioprecursors described above in the therapeutic field, for example dermatological, or cosmetic.
• the present invention also relates to the compositions containing at least one bioprecursor according to the invention, in a topical formulation acceptable for the intended application, therapeutic, dermatological or cosmetic.
• the invention also relates to the use of a bioprecursor as defined above for the preparation of a therapeutic, dermatological or cosmetic composition.
• compositions containing at least one bioprecursor according to the invention may be care compositions for the face or the body, slimming care compositions, solar compositions, perfume compositions, make-up compositions, such as foundations or powders, compositions for lips in the form of balms, "lipsticks” or “gloss”, or mascara compositions, hygiene compositions such as shower gels or deodorants.
• the acceptable medium generally comprises water, and / or a mixture of water and fatty substances, and / or a mixture of fatty substances, and / or a mixture of water and silicone.
• suspension solution, paste, ointment, gel aqueous, hydroalcoholic gel, cream, lotion, powder, soap, spray, foam.
• compositions may also contain acceptable cosmetic or dermatological additives.
• additives may be, in particular but not exclusively, surfactants, fatty substances, such as oils, free active molecules, such as moisturizers or hydrophilic or lipophilic active agents, preservatives, perfumes, chelators, pigments filters, sequestering agents, colorants, fillers, humectants, thickeners, such as gelling agents, texturizing agents, flavoring agents, solvents, etc.
• Nonlimiting, additives that can be used in the compositions of the present invention are the following: oils, chosen in particular from: silicone oils, linear or cyclic, volatile or non-volatile, such as polydimethylsiloxanes (dimethicones), polyalkylcyclosiloxanes (cyclomethicones) and polyalkylphenylsiloxanes (phenyldimethicones); synthetic oils such as fluorinated oils, alkylbenzoates and branched hydrocarbons such as polyisobutylene; vegetable oils and especially soy or jojoba; and mineral oils such as paraffin oil; waxes, such as ozokerite, polyethylene wax, beeswax or carnauba wax; the silicone elastomers obtained especially by reaction, in the presence of a catalyst, of a polysiloxane having at least one reactive group (especially hydrogen or vinyl) and bearing at least one alkyl group (especially methyl) or phenyl, terminal and / or lateral,
• thickeners and / or gelling agents and in particular hydrophilic or amphiphilic crosslinked or non-crosslinked homo- and copolymers of acryloylmethylpropanesulphonic acid (AMPS) and / or acrylamide and / or acrylic acid and / or salts or acrylic acid esters; xanthan or guar gum; cellulosic derivatives; and silicone gums (dimethiconol); humectants, such as polyols, including glycerine, propylene glycol and sugars, and glycosaminoglycans such as hyaluronic acid and its salts and esters; organic filters, such as dibenzoylmethane derivatives (including butyl-methoxydibenzoylmethane), cinnamic acid derivatives (including ethylhexyl-methoxycinnamate), salicylates, para-aminobenzoic acids, ⁇ - ⁇ - 1 -diphenyl
• bioprecursors and compositions according to the invention are advantageously insensitive or insensitive to external factors such as light or heat, pH variations and additives such as surfactants, solvents, catalysts metal. This stability makes it possible to maintain the desired efficiency and the visual appearance and odor of the compositions.
• compositions are those conventionally used in the field under consideration, e.g. cosmetic and dermatological.
• the amount of bioprecursor in the compositions of the invention depends on many factors, among which may be mentioned, without limitation, the type of formulation, the nature of the bioprecursor, the mode of administration, the severity of the pathology. possible to treat, the intensity of the desired effect, and others.
• the amount of bioprecursor can for example be between 0.001% and 20%, preferably between 0.005% and 15%, more preferably between 0.01% and 10%, advantageously between 0.05% and 5%, or between about 0.08% and about 2%.
• the present invention also relates to the use of a polyphenol as described herein, in particular comprising all or part of its hydroxyl functions protected by groups A, as a vector for penetrating one or more biologically active molecules, such as those described herein, in the skin, and more particularly in one or more of the layers of the skin.
• bioprecursors of the invention may be manufactured by various methods known from the prior art, such as methods for acylating phenol derivatives (see Protective Groups in Organic Synthesis, Green TW, second edition, (1991)). , page 162), methods of selective deprotection of phenol esters using enzymatic systems.
• the present invention relates in particular to a process for the manufacture of bioprecursors of the invention comprising at least the following steps: a) protection of the polyphenol by per-esterification, such as peracetylation, with an AZ compound, Z being a function capable of react with an OH function of the polyphenol to generate the ester bond between the polyphenol and A, b) selective deprotection so as to obtain one or more free OH functions of the polyphenol, and c) coupling of the intermediate obtained after step b) with the biologically active molecule B previously activated.
• per-esterification such as peracetylation
• the peracetates can be prepared by peracetylation of resveratrol under standard conditions in the presence of pyridine and an excess of acetic anhydride as described by H. Aft in Journal of Organic Chemistry. , 26, (1961), 1958-1963. The reaction is carried out by heating at 80 ° C. for some hours. The synthesis is conventional and leads to the desired product with very good yields.
• the de-esterification, eg deacetylation, selective of a peresterified compound, eg peracetylated can be carried out using an enzyme, such as for example a lipase microbial, as described by Nicolosi et al. in Journal of Molecular Catalysis B: Enzymatic, 16, (2002), 223-229.
• the enzyme used is, for example, Candida antarctica lipase immobilized on a polypropylene resin. Lipase is marketed by Novo Nordisk under the name Novozym SP435 ® .
• the de-esterification or deacetylation catalyzed by the lipase can be carried out either by the hydrolysis reaction in the aqueous medium, or by an alcoholysis in an organic solvent. Most often we use a medium “alcohol” and we talk about an alcoholysis.
• the reaction is carried out under "mild” conditions of temperature (15 to 75 ° C) and pH (5-8, if aqueous medium).
• the product is generally obtained by simple filtration of the enzyme and concentration under reduced pressure of the reaction medium.
• Chlorination with thionyl chloride is the most used method because the products formed are easily obtained and used without isolation (see J. S. Pizey, Synthetic Reagents, 1, (1974), 321).
• the reaction is carried out at room temperature in an anhydrous solvent such as dichloromethane.
• the coupling between an alcohol and an acid may be catalyzed by a dehydrating agent such as, for example, dicyclohexylcarbodiimide (DCC).
• a dehydrating agent such as, for example, dicyclohexylcarbodiimide (DCC).
• DCC dicyclohexylcarbodiimide
• the reaction conditions are described by M. Smith et al in J. Am. Chem. Soc., 80, (1958), 6204.
• the present invention also relates to a cosmetic skin treatment process comprising applying to said skin a composition as described above, the bioprecursor contains a precursor B of cosmetically active compound.
• the invention relates in particular to a cosmetic process for releasing polyphenol and active molecules B at the Stratum corneum or living tissues of the skin by topical application to the skin of a composition as defined above.
• the invention also relates to a dermatological treatment method of applying to the skin a composition as described above, the bioprecursor contains a precursor B of dermatologically active compound.
• the invention also relates to a method of therapeutic treatment consisting in applying to the skin a composition as described above, the bioprecursor contains a precursor B of pharmaceutical compound to be delivered transcutaneously, including systemic action.
• the mixed ester 3,5-diacetyl-4'-lipoylresveratrol (1) is obtained in four stages by esterification of resveratrol diacetate with lipoyl chloride in the presence of triethylamine and DMAP (dimethylaminopyridine) in tetrazhydrofuran (THF) at 0 0 C.
• Resveratrol diacetate is obtained by enzymatic alcoholysis of resveratrol triacetate (1.1) with Novozyme® SP435 as described by Nicolosi et al. (Journal of Molecular Catalysis B: Enzymatic, 16, (2002), 223-229) with some modifications, namely: tert-butyl methyl ether (TBME) was replaced by acetonitrile and the amount of enzyme was decreased to 20% w / w.
• TBME tert-butyl methyl ether
• the alcoholysis of resveratrol triacetate is carried out on a scale of 200 g / l of resveratrol triacetate with n-butanol in the presence of 20% w / w of Novozyme SP435 in acetonitrile at 65 ° C. and in 15 hours. .
• the crude product is obtained by filtration of the enzyme and by concentration under reduced pressure of the reaction medium.
• the crude product is a mixture of 88% diacetate (1.2) and 12% monoacetate. It was purified by chromatography on a silica column with cyclohexane / ethyl acetate (4/1 v / v) as eluent.
• lipoic acid chloride (DL-thioctic acid) was carried out under argon at room temperature following a standard protocol: the lipoic acid (5 g, 24 mmol) is solubilized in dichloromethane (40 mL ) and SOCI 2 (1, 3 eq) is added dropwise. After stirring for 1 hour at room temperature, the lipoic acid chloride formed is poured onto a solution of resveratrol diacetate (1.2) (6 g, 19 mmol) in THF (100 mL), containing triethylamine (3 eq. ) and DMAP (0.45 eq).
• the mixed ester 3,5-diacetate-4'-acetylferulate resveratrol is obtained in five steps by esterification of resveratrol diacetate with O-acetyl ferulic acid chloride in the presence of triethylamine and DMAP in THF at 0 ° C.
• the ferulic acid (10 g, 51 mmol) is solubilized in 10O mL of anhydrous THF, under argon.
• Triethylamine (8.7 mL, 61 mmol, 1.2 eq) was then charged rapidly followed by DMAP (3.34 g, 27 mmol, 0.5 eq) at room temperature and under argon.
• acetic anhydride (5.9 ml, 61 mmol, 1.2 eq) is charged over 3 min at room temperature. Stirring is maintained at room temperature for 18 h, then the medium is transferred to a separatory funnel.
• This medium is diluted with 100 ml of THF, acidified with 40 ml of 5% v / v HCl and the organic phase is washed with 5 ⁇ 40 ml of H 2 O. The final organic phase is dried over MgSO 4 , filtered. then evaporated to dryness on a rotary evaporator (40 ° C., 30mbar). 9.5 g of a crude yellow solid are obtained with a crude yield of 79% and a molar purity assayed by NMR of 86%. The product is engaged in the next step without purification.
• the resveratrol diacetate (1.92 g, 5 mmol) was loaded and solubilized in 10 mL of anhydrous THF. Triethylamine (2.15 ml, 15 mmol, 3 eq) and then the DMAP (121 mg, 1 mmol, 0.2 eq) are rapidly charged. A solution of O-acetyl ferulic acid chloride (1.27 g, 5 mmol, 1 eq) solubilized in 10 ml of anhydrous THF + 3 ml of dichloromethane is charged at ambient temperature.
• the medium is transferred to a separating funnel, diluted with 50 ml of dichloromethane and acidified with 5% v / v HCl.
• the organic phase is washed with 20 ml of saturated aqueous NaHCO 3 and then with 4 ⁇ 30 ml of H 2 O.
• the final organic phase is dried over MgSO 4 , filtered and evaporated to dryness on a rotary evaporator.
• the mixed ester 3,5-diacetate ⁇ 4'-succinyltocopherol is obtained in three stages by esterification of resveratrol diacetate with tocopherylsuccinate chloride in the presence of triethylamine and DMAP in THF at 0 ° C.
• Racemic ⁇ -tocopherol (10.2 g, 23 mmol) and succinic anhydride (1.5 eq) are dissolved in 50 mL of dichloromethane.
• DMAP 0.5 eq
• triethylamine (1.05 eq) are added thereto and the reaction is monitored by thin layer chromatography (TLC) (ethyl acetate / cyclohexane 50/50 v / v). The reaction mixture is stirred overnight at room temperature and protected from light.
• TLC thin layer chromatography
• the mixture is diluted with 40 ml of dichloromethane, washed with 5% v / v HCl, then with H 2 O and the organic phase is dried over MgSO 4 and then evaporated to dryness on a rotary evaporator.
• the crude product is obtained in quantitative yield. This crude product is solubilized in diethyl ether and this solution is filtered through a silica cake. The filtrate obtained is evaporated to dryness the rotary evaporator. An oil is obtained which solidifies at 4 ° C.
• the product is isolated with a yield of 70% and a molar purity of 94% (measured by 13 C NMR).
• tocopherylsuccinate chloride was carried out under argon at room temperature following a standard protocol (a slight excess of SOCI 2 , triethylamine, dichloromethane) at room temperature and under argon.
• the acid chloride is not isolated and is engaged as such in the next step of esterification.
• the mixed ester of luteolin and vitamin E (triacetate-monosuccinyltocopheryl luteolin) is obtained in four stages by esterification of luteolin triacetate with vitamin E succinate chloride in the presence of triethylamine and DMAP in THF to O 0 vs.
• Resveratrol tricaproate (trihexanoate) is obtained by esterification of resveratrol with hexanoyl chloride in the presence of triethylamine in THF at room temperature.
• Example 6 Synthesis of Resveratrol 3,5-diacetate-4'-caproate (6)
• Compound 6 is synthesized as described in Example 1, replacing the lipoic acid chloride with hexanoyl chloride (caproyl).
• Resveratrol diacetate (4 g, 12.8 mmol) was loaded and solubilized in 60 mL of anhydrous THF.
• Triethylamine (1.5 eq) and then hexanoyl chloride (2.72 mL, 1.5 eq) are added dropwise in an ice bath (0 ° C.).
• the medium After stirring for 17 hours at room temperature, the medium is transferred to a separatory funnel, washed with 10 ml of saturated sodium bicarbonate solution and then extracted with three times 20 ml of ethyl acetate. The organic phase is washed with three times 20 ml water, then dried over anhydrous MgSO 4 .
• the crude product is obtained after concentration under reduced pressure with a yield of 90% and a mass purity of 80%.
• the buffers used in the bio-hydrolysis assays are: 50 mM Tris (tris [hydroxymethyl] aminomethane) pH 7.3 and pH 8; 50 mM Na-acetate pH 5.5; 50 mM MES (2- [N-morpholino] -ethanesulfonic acid) pH 6 and 50 mM phosphate pH 6.5.
• the precursors are solubilized in acetonitrile at a concentration of 1 g / l.
• 50 ⁇ l of substrate and 50 ⁇ l of acetonitrile are added to 900 ⁇ l of enzymatic extract in the pH buffer chosen.
• the reaction mixtures are incubated at 35 ° C. without shaking and protected from light.
• the evolution of the bio-hydrolysis is determined by HPLC (high performance liquid chromatography) reversed phase polarity.
• the controls are made in the same solutions without enzymatic extracts of the skin, to determine the chemical stability of the products.
• the enzyme used is bovine pancreatic cholesterol esterase, class EC 3.1.1.13 (SIGMA C-3766).
• the precursors are prepared as described in Example 9a. The results are shown in Table 1 below. Table 1
• Stratum corneum lipases hydrolyze the acetyl groups of the precursor and lead to an intermediate (Res-succinate-Vit E) which itself has an antioxidant activity thanks to the OH group of the di-acetylated resveratrol part.
• Emulium Delt ⁇ r cetyl alcohol + glyceryl stearate + PEG-75 + ceteth-20 stearate + steareth-20.
• the formulation thus obtained has good stability after 56 days in an oven at 45 ° C.
• Formulation 11.2 Formulation Water in Oil (W / O)
• Bioprecursor according to example 1 0.10
• Formulation 11.9 Formulation Water in Oil (W / O)

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Dermatology (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Emergency Medicine (AREA)
• Epidemiology (AREA)
• Birds (AREA)
• Toxicology (AREA)
• Biochemistry (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Child & Adolescent Psychology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Cosmetics (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Heterocyclic Compounds Containing Sulfur Atoms (AREA)
• Pyrane Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=35788537

Family Applications (1)

Country Status (6)

Cited By (29)

Families Citing this family (18)

Citations (3)

Family Cites Families (7)

• 2005
  • 2005-06-17 FR FR0506169A patent/FR2887251B1/fr not_active Expired - Fee Related
• 2006
  • 2006-06-16 JP JP2008516380A patent/JP5469339B2/ja not_active Expired - Fee Related
  • 2006-06-16 WO PCT/FR2006/001375 patent/WO2006134282A1/fr not_active Ceased
  • 2006-06-16 EP EP06778610.3A patent/EP1893555B1/fr not_active Not-in-force
  • 2006-06-16 ES ES06778610.3T patent/ES2527341T3/es active Active
  • 2006-06-16 US US11/922,331 patent/US9067908B2/en not_active Expired - Fee Related

Patent Citations (3)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events